Singapore – Dornier MedTech (Dornier), a global leader in innovative kidney stone management, announced the introduction in Singapore a new laser portfolio comprising of Dornier Medilas H Solvo 35 and Dornier Medilas H 140 for the treatment of urological stones and benign prostate hyperplasia, at the annual Asia Pacific UroFair 2018 taking place at Grand Hyatt, Singapore, 12-14 July 2018.

The Dornier Medilas H Solvo 35 and Dornier Medilas H 140 are the new generation of holmium lasers that aim to improve workflow efficiency in the operating room. They are the latest additions to Dornier’s portfolio of market-leading holmium laser brands. The products have received US FDA approval and CE Mark and are now commercially available in Europe and the US.

Singapore will be the first market in Asia for Dornier MedTech’s debut of the H Solvo 35 and H 140. Dornier MedTech is a market leader in the region, where majority of urologists rely on its trusted products since 1983 to deliver treatments to their patients. Incidence of stone disease in Asia is rapidly growing in parallel with the rising rates of obesity and diabetes. In Singapore, about 15% of the population has kidney stone disease. Recurrence occurs in almost 25% to 50% of all cases.

Abel Ang, President and CEO of Dornier MedTech said: “The Dornier Medilas H Solvo 35 and H 140 are the results of extensive customer research and our commitment to innovation, and we are proud to add them to our expanding portfolio of market leading patented lasers and fibres to meet the needs of a growing market for non-invasive urology surgery. The versatility and unique technology of H Solvo 35 and H 140 can be applied across a variety of stones, enhancing clinical practice and enabling urologists and clinicians achieve better results for their patients.”

Dornier MedTech will exhibit Dornier Medilas H Solvo 35 and Dornier Medilas H 140 at booth A10 at the UroFair 2018.